These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 30371575)

  • 1. Differentiated Thyroid Cancer Outcomes After Surgery and Activity-Adjusted 131I Theragnostics.
    Avram AM; Rosculet N; Esfandiari NH; Gauger PG; Miller BS; Cohen M; Hughes DT
    Clin Nucl Med; 2019 Jan; 44(1):11-20. PubMed ID: 30371575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preablation 131-I scans with SPECT/CT contribute to thyroid cancer risk stratification and 131-I therapy planning.
    Avram AM; Esfandiari NH; Wong KK
    J Clin Endocrinol Metab; 2015 May; 100(5):1895-902. PubMed ID: 25734251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preablation 131-I scans with SPECT/CT in postoperative thyroid cancer patients: what is the impact on staging?
    Avram AM; Fig LM; Frey KA; Gross MD; Wong KK
    J Clin Endocrinol Metab; 2013 Mar; 98(3):1163-71. PubMed ID: 23430789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incremental diagnostic value of SPECT/CT with 131I scintigraphy after radioiodine therapy in patients with well-differentiated thyroid carcinoma.
    Maruoka Y; Abe K; Baba S; Isoda T; Sawamoto H; Tanabe Y; Sasaki M; Honda H
    Radiology; 2012 Dec; 265(3):902-9. PubMed ID: 23012466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High Level of Agreement Between Pretherapeutic 124I PET and Intratherapeutic 131I Imaging in Detecting Iodine-Positive Thyroid Cancer Metastases.
    Ruhlmann M; Jentzen W; Ruhlmann V; Pettinato C; Rossi G; Binse I; Bockisch A; Rosenbaum-Krumme S
    J Nucl Med; 2016 Sep; 57(9):1339-42. PubMed ID: 27151981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-Response Relationship in Differentiated Thyroid Cancer Patients Undergoing Radioiodine Treatment Assessed by Means of 124I PET/CT.
    Wierts R; Brans B; Havekes B; Kemerink GJ; Halders SG; Schaper NN; Backes WH; Mottaghy FM; Jentzen W
    J Nucl Med; 2016 Jul; 57(7):1027-32. PubMed ID: 26917706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differentiated thyroid carcinoma: Incremental diagnostic value of
    Zilioli V; Peli A; Panarotto MB; Magri G; Alkraisheh A; Wiefels C; Rodella C; Giubbini R
    Endocrine; 2017 Jun; 56(3):551-559. PubMed ID: 27709475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iodine-131 SPET/CT and 18F-FDG PET/CT for the identification and localization of mediastinal lymph node metastases from differentiated thyroid carcinoma.
    Xu YH; Shen CT; Xue YL; Qiu ZL; Luo QY
    Hell J Nucl Med; 2013; 16(3):199-203. PubMed ID: 24251307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 124I PET/CT to Predict the Outcome of Blind 131I Treatment in Patients with Biochemical Recurrence of Differentiated Thyroid Cancer: Results of a Multicenter Diagnostic Cohort Study (THYROPET).
    Kist JW; de Keizer B; van der Vlies M; Brouwers AH; Huysmans DA; van der Zant FM; Hermsen R; Stokkel MP; Hoekstra OS; Vogel WV; ;
    J Nucl Med; 2016 May; 57(5):701-7. PubMed ID: 26609180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of FDG PET/CT on the follow-up of patients of differentiated thyroid carcinoma with negative 131I whole-body scan and elevated thyroglobulin levels: correlation with clinical and histopathologic characteristics and long-term follow-up data.
    Vural GU; Akkas BE; Ercakmak N; Basu S; Alavi A
    Clin Nucl Med; 2012 Oct; 37(10):953-9. PubMed ID: 22899202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensitivity of 123I whole-body scan and thyroglobulin in the detection of metastases or recurrent differentiated thyroid cancer.
    de Geus-Oei LF; Oei HY; Hennemann G; Krenning EP
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):768-74. PubMed ID: 12029550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 123I isotope as a diagnostic agent in the follow-up of patients with differentiated thyroid cancer: comparison with post 131I therapy whole body scanning.
    Alzahrani AS; Bakheet S; Al Mandil M; Al-Hajjaj A; Almahfouz A; Al Haj A
    J Clin Endocrinol Metab; 2001 Nov; 86(11):5294-300. PubMed ID: 11701695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pulmonary metastases in differentiated thyroid cancer: efficacy of radioiodine therapy and prognostic factors.
    Song HJ; Qiu ZL; Shen CT; Wei WJ; Luo QY
    Eur J Endocrinol; 2015 Sep; 173(3):399-408. PubMed ID: 26104753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of radioactive iodine in thyroid remnant ablation and treatment of well differentiated thyroid carcinoma.
    Lin JD; Kao PF; Chao TC
    Br J Radiol; 1998 Mar; 71(843):307-13. PubMed ID: 9616241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are there disadvantages in administering 131I ablation therapy in patients with differentiated thyroid carcinoma without a preablative diagnostic 131I whole-body scan?
    Salvatori M; Perotti G; Rufini V; Maussier ML; Dottorini M
    Clin Endocrinol (Oxf); 2004 Dec; 61(6):704-10. PubMed ID: 15579184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 18F-FDG-PET/CT in Patients Affected by Differentiated Thyroid Carcinoma with Positive Thyroglobulin Level and Negative 131I Whole Body Scan. It's Value Confirmed by a Bicentric Experience.
    Bertagna F; Albano D; Bosio G; Piccardo A; Dib B; Giubbini R
    Curr Radiopharm; 2016; 9(3):228-234. PubMed ID: 27210819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Results of radioiodine therapy in patients with pulmonary metastases of differentiated thyroid cancer].
    Ono Y; Yamamoto Y; Nishiyama Y; Nakano S; Takahashi K; Kawasaki Y; Satoh K; Ohkawa M; Tanabe M
    Kaku Igaku; 2000 Nov; 37(6):661-70. PubMed ID: 11193452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can (18)F-FDG-PET/CT be generally recommended in patients with differentiated thyroid carcinoma and elevated thyroglobulin levels but negative I-131 whole body scan?
    Bannas P; Derlin T; Groth M; Apostolova I; Adam G; Mester J; Klutmann S
    Ann Nucl Med; 2012 Jan; 26(1):77-85. PubMed ID: 22006540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcomes following empiric radioiodine therapy in patients with structurally identifiable metastatic follicular cell-derived thyroid carcinoma with negative diagnostic but positive post-therapy 131I whole-body scans.
    Sabra MM; Grewal RK; Tala H; Larson SM; Tuttle RM
    Thyroid; 2012 Sep; 22(9):877-83. PubMed ID: 22827641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation?
    Mazzaferri EL; Kloos RT
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1490-8. PubMed ID: 11932270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.